Concordia University

今年4月，央视财经频道《中国好医生》以22分钟专题报道，深度剖析了由领博生物科技（杭州）有限公司（以下简称“领博生物”）自主研发的PULSSIBLE®生物型人工血管在破解尿毒症患者血透困境中的突破性价值。作为国内唯一获央视报道的国产人工血管产品，时隔三月，这一标杆性项目迎来关键里程碑——7月15日，PULSSIBLE®生物型人工血管注册临床试验已顺利完成全部患者入组（总计近400例）。该试验由重庆医科大学附属第一医院牵头，联合全国六家顶尖中心共同开展。参与本次试验的各中心研究者对该产品的安全性和有效性给予了充分肯定，同时高度认可其在血管疾病治疗中展现的应用潜力。01创下多个国内首个，领博生物率先破局生物型人工血管打造生物型人工血管技术门槛极高。放眼全球，掌握该技术的企业仅是寥寥，而要想实现临床安全验证并最终成功产业化更是困难重重。正是在这样的背景下，领博生物率先破局生物型人工血管，并创下多个“首个”记录。公司自主研发的PULSSIBLE®不仅是国内首个完成FIM临床试验、首个完成注册临床试验全部患者入组，以及首个获得CCTV专访的生物型人工血管，更保持着目前国内最长的生物型人工血管植入时间记录。02最长植入时间达3年，累计完成患者透析穿刺超500次作为国内首个完成注册临床试验全部患者入组的生物型人工血管产品，此次入组完成为产品正式申报奠定了核心数据基础，成为其提交上市注册申请前的关键里程碑。这不仅标志着血管再生医学领域取得重大突破，更是国产生物型人工血管迈向临床应用的关键一步。据悉，本次“评价生物型人工血管用于终末期肾病患者血液透析血管通路建立安全性及有效性评价的前瞻性、多中心、随机对照、非劣效试验”手术达到预期效果，产品缝合效果优异，具有接近天然血管的缝合手感，患者术后未发生渗血、免疫排斥、吻合口断裂、血管塌陷等异常情况。进一步印证了该产品的技术成熟度、可靠性及临床价值。值得强调的是，PULSSIBLE®FIM临床试验数据同样亮眼。目前，所有入组患者血管植入时间均超2年，其中最长植入时间达3年，累计完成透析穿刺超500次。产品展现出了良好的再生特性和即刻穿刺性（可于24小时内即刻穿刺），性能优于EPTFE人工血管。03适应症领域拓展至心脏搭桥，大动物模型保持6个月通畅PULSSIBLE®在血液透析领域所取得的临床数据，验证了该产品在血液透析适应症中的安全性、有效性及再生性等特性，为产品在该适应症中应用打下基础，也为产品拓展其他适应症提供了临床依据。目前，PULSSIBLE®在心脏搭桥领域的探索已取得突破性进展。在大动物实验中，该人工血管植入后保持6个月通畅，证明其在冠状动脉旁路移植术中的应用价值。据悉，该项目力争尽快启动人体临床试验，或有望成为中国首个进入心脏搭桥人体临床阶段的生物型人工血管产品。04国内知名组织工程专家创立，加速中国首创人工血管临床落地领博生物由国内组织工程知名专家、国家杰青、南开大学药物化学生物学全国重点实验室主任、美国医学与生物工程院Fellow孔德领教授与资深医疗产业化团队于2019年共同成立，致力于研发可替代、可修复人类组织与器官的组织工程再生材料产品，矢志成为全球领先的组织再生修复与再生人工器官研发与制造的平台型企业。孔德领教授作为南开大学教授、博士生导师，国家杰出青年科学基金获得者，教育部创新团队和国家自然科学基金创新研究群体带头人，国际生物材料学会Fellow，美国医学与生物工程院Fellow，国际血液净化学会环太平洋地区理事，国际组织工程学会“组织工程血管学组”主要发起人和副组长，入选新世纪百千万人才工程、天津市杰出人才。曾任协和学者特聘教授和生物活性材料教育部重点实验室主任、南开大学生命科学学院院长、南开大学科学技术研究部部长，现任药物化学生物学全国重点实验室主任。主持国家重点研发计划、国家自然科学基金等项目30余项，发表SCI论文480余篇，H因子99，被引用3.5万次，授权发明专利60余件，10件发明专利实现转化。首创聚合物纤维增强型细胞外基质人工血管制备技术，研发了可再生的生物型人工血管。以第一完成人荣获天津市自然科学一等奖、天津市技术发明一等奖、中国发明协会发明创业奖成果奖一等奖、全国颠覆性技术创新大赛优胜奖等，指导学生获得中国“互联网+”大学生创新创业大赛金奖，带领团队荣获全国侨联系统先进组织、天津市模范集体。依托孔德领教授学术基因，及其主导构建的医工转化体系，数年发展，领博生物先后斩获科技部颠覆性技术创新大赛最高奖、中国发明协会一等奖，同时牵头并参与国家科技部重点研发计划等，公司技术实力获国家级权威认可。随着公司发展逐步深入，领博生物吸引了泰煜投资、新兆源资本、博行资本、磐霖资本、泰鲲基金、华大共赢、天士力资本等专业医疗资本与产业链协同投资机构加入，形成覆盖研发至产业化的全生命周期资本赋能体系，为生物型人工血管产业化打下基础。公司联合创始人CEO许鹏赟先生表示：项目现阶段的高效运转是在孔德领教授研发团队数十年的研究成果、南开大学大力支持、资深医疗产业化团队深度运营、临床专家充分参与，以及专业投资人团队共同帮助的基础上完成的。同时，项目的阶段性成功更离不开国家“支持产学研项目”政策的引导。公司将不断努力，给患者带去更多革命性的再生医学产品。回顾一路走来，领博生物所取得的成绩正是公司发展势能的直接体现。如今，随着注册临床试验入组工作的完成，PULSSIBLE®在血液透析、血管重建等领域的应用价值也将加速兑现，有望重塑国内人工血管市场格局。05寄语泰煜投资创始人&总经理纪添荣博士：作为领博生物最早的投资人之一，很高兴参与和见证了领博生物的多个里程碑时刻，我们持续看好公司的研发能力和产业化效率，也期待人工血管的下一个里程碑时刻的到来。博行资本投资总监丛博：恭喜领博生物顺利完成国内首款生物型动静脉造瘘人工血管的临床入组，产品较现有的EPTFE材料有显著优势，期待领博人工血管上市后造福中国患者。博行资本非常看好领博生物的技术前景，自公司成立以来博行资本已连续两轮完成对领博生物投资，未来将持续支持公司发展。磐霖资本管理合伙人薛孟军：恭喜领博生物完成国内首条小口径再生血管动静脉造瘘的临床试验大样本入组，即将造福国内血透患者，在中国再生血管领域具有里程碑意义。领博生物是国内再生医学组织工程领域科学技术成果转化的成功案例，也是磐霖眼中典型的“源头创新”型企业，期待领博生物继续在冠脉搭桥适应症等更具挑战的领域不断取得突破。天士力资本管理合伙人王晨：再生医学一直在致力于满足器官修复、再生的需求。尤其是脱细胞的组织工程血管移植物，被认为是心血管重建领域的前沿技术。该技术有可能较好解决血管通路重建和保持长期良好通畅性。在此领域，领博生物是国内最领先的企业。在领博团队努力下，终于完成全部注册临床试验入组，显示了技术的先进性和团队的高效性。我们对此表示热烈的祝贺。希望领博生物能顺利拿到国内第一张再生型人工血管批准证书。如果您想对接文章中提到的项目，或您的项目想被动脉网报道，或者发布融资新闻，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。文中如果涉及企业信息和数据，均由受访者向分析师提供并确认。动脉网，未来医疗服务平台

MEQUON, Wis., June 23, 2025 /PRNewswire/ -- Milwaukee Capital Partners LLC, Milwaukee, WI (MCP) is pleased to announce the acquisition of MPP Group LLC., Mequon, WI (MPP), effective May 1, 2025. Joining MCP on the acquisition of MPP was an investment by Concordia University Ventures (CU Ventures) led by Daniel Sem. MPP Group will maintain its company headquarters in the Mequon Technical Park, a rapidly growing area of scientific and soft manufacturing excellence as they advance their investment interests into pharmaceutical contract research and development. Thomas Kintis, Managing Partner of MCP, will serve as Board Chairman and Senior Advisor. Benjamin Nelson, Ph.D., MPP's current President and Head of Product Development, will continue to lead MPP Groups ongoing business interests and daily operations. Milwaukee Capital Partners, LLC (MCP), a prominent entity in private equity investment, has consistently demonstrated a commitment to advancing emerging technologies. Their strategic decisions have often been underscored by a vision for growth and innovation, making them an influential player in the investment landscape. With their latest acquisition, MCP is poised to expand their portfolio and drive significant advancements within the pharmaceutical industry. The acquisition of MPP by MCP marks a new chapter in the company's 10-year history and will allow for significant cash infusion to advance specialized analytical services and additional capital investments throughout the growth of the organization. Thomas Kintis offered that "with a burgeoning focus on repatriating pharmaceutical development and manufacturing into the US, we believe that MPP is well positioned for partnering with pharma and biotech both domestically and internationally to capitalize on these opportunities." MPP Group specializes in providing contract analytical services and product research and development. Their primary focus is on development and formulations of injectable drug products, and the breath of their services includes but is not limited to analytical development and validation, formulations development, container/closure screening, and elemental impurities analysis/risk assessments. The Southeastern Wisconsin location boasts significant access to highly talented scientists and engineers - providing access to expertise in advanced sciences, drug development and manufacturing - drawing from a highly qualified professional work force in Illinois, Indiana, Michigan, Minnesota and Wisconsin - and central to some of the Midwest's finest universities within just a few hours of the facility, as well as only a 30 minutes' drive to General Mitchell Field International Airport and one hour to Dane County Regional Airport in Madison. Established in 2016 by Michal A. Major, Ph.D., the former president and founder of Cambridge Major Laboratories, MPP Group emerged on the CRO front to maximize access for emerging pharma and biotech, with limited or non-existent testing and development capabilities. Today, MPP Group prides itself on careful partnerships that demand full attention of the team, honest engagement and time bound key deliverables at a level of personalization not commonly experienced in the challenging space of contract services. The 35,000 sq ft FDA inspected and approved site consists of 5 laboratories equipped with qualified and validated instrumentation and includes over 12,000 sq ft of available space for future expansion for sterile manufacturing. Media Contact: For additional information regarding MCP and further investment opportunities please contact Thomas Kintis at [email protected]. For information regarding MPP Group's services, please contact Ben Nelson at [email protected]. For information regarding CU Ventures please contact Daniel Sem at [email protected]. SOURCE MPP Group LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

WEDNESDAY, March 12, 2025 -- Knee or hip replacement is a major surgery, and many people must lean hard on their spouses to care for them during weeks to months of recuperation. But all that hassle is absolutely worthwhile for the one providing care for their temporarily disabled partner, a new study suggests. Spouses experience significant improvements in their quality of life following their partner’s knee or hip replacement procedure, researchers reported at a meeting of the American Academy of Orthopedic Surgeons this week in San Diego. “It is well studied that the patient's quality of life improves following surgery, but now we know it will also improve for spouses,” lead researcher Dr. Nicolas Jozefowski , a recent graduate of Loyola University School of Medicine in Chicago, said in a news release. “Most spouses assume a caregiving role when their partner has joint replacement surgery and they are sacrificing a bit in terms of their quality of life, but we can show it will improve with these data,” Jozefowski added. “Patients can have less pain, and couples can do more things together." Joint replacement surgery has become more common as the U.S. population grows and ages, researchers said in background notes. About 544,000 total hip replacements and 790,000 total knee replacements take place each year. In fact, the surgery has become so rote that it’s now performed mostly on an outpatient basis, with patients leaving the hospital under their own steam within hours of the procedure. That means that spouses have become the primary caregivers following joint replacement surgery, shifting the responsibility of nursing a patient through recovery to their families, researchers said. Spouses of people in chronic pain tend to have a lower quality of life and higher levels of depression, researchers noted. The point of the new study was to see if this was also true among spouses of joint replacement patients. For the study, researchers surveyed 100 spouses of joint replacement patients -- 50 involving hip replacement and 50 involving knee replacement. The survey was completed an average of about 2 years following the surgery. About 70% of spouses said their quality of life was slightly or significantly better following their partner’s hip replacement. Likewise, 76% of spouses of knee replacement patients reported improved quality of life, results show. On a 1 to 5 scale for how often their spouse needs assistance, running from “never” to “always,” spouses of hip replacement patients responded with an average 1.4 at least one year after surgery. Spouses of knee replacement patients returned an average 1.8 when rating the assistance they continued to render their partner at least a year after surgery. Jozefowski said surgeons can use the findings to counsel patients and spouses on what to expect. "A lot of times what we see in clinical practice is it is the spouse that prompts the patient to seek care for a variety of reasons, such as not being able to do everyday activities," senior researcher Dr. Nicholas Brown , an associate professor with Loyola Medicine, said in a news release. "This study further validates the effectiveness of knee and hip replacements for patients' pain and well-being, as well as those around them,” Brown said. “It confirms the transformational power of this surgery and the ways it benefits their spouses and families." Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.